Richard Perry

Richard Perry

Auto-generated profile, based on publicly available information

Richard Perry

Department of Translational Neuroscience and Stroke, University College London Queen Square Institute of Neurology, London, England, UK

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in The Lancet
Verified
Journal Article
Closed access
RPRichard J Perry
Richard J Perry
ATArina Tamborska
Arina Tamborska
BSBhagteshwar Singh
Bhagteshwar Singh
BCBrian Craven
Brian Craven
RMRichard Marigold
Richard Marigold
LZLaura Zambreanu
Laura Zambreanu

5 November 2020 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
RPRichard J Perry
Richard J Perry
CSCraig J Smith
Craig J Smith
CChristine Roffe
Christine Roffe
RSRobert J Simister
Robert J Simister
SNSaravanan Narayanamoorthi
Saravanan Narayanamoorthi
DWDavid J Werring
David J Werring
Objective: We set out to determine which characteristics and outcomes of stroke are associated with COVID-19.Methods: This case-control study included patients admitted with stroke to 13 hospitals in England and Scotland between 9 March and 5 July 2020. We collected data on 86 strokes (81 ischaemic strokes and 5 intracerebral haemorrhages) in patients with evidence of COVID-19 at the time of stroke onset (cases). They were compared with 1384 strokes (1193 ischaemic strokes and 191 intracerebral haemorrhages) in patients admitted during the same time period who never had evidence of COVID-19 (controls). In addition, the whole group of stroke admissions, including another 37 patients who appeared to have developed COVID-19 after their stroke, were included in two logistic regression analyses examining which features were independently associated with COVID-19 status and with inpatient mortality.Results: Cases with ischaemic stroke were more likely than ischaemic controls to occur in Asians (18.8% vs 6.7%, p<0.0002), were more likely to involve multiple large vessel occlusions (17.9% vs 8.1%, p<0.03), were more severe (median National Institutes of Health Stroke Scale score 8 vs 5, p<0.002), were associated with higher D-dimer levels (p<0.01) and were associated with more severe disability on discharge (median modified Rankin Scale score 4 vs 3, p<0.0001) and inpatient death (19.8% vs 6.9%, p<0.0001). Recurrence of stroke during the patient’s admission was rare in cases and controls (2.3% vs 1.0%, NS).Conclusions: Our data suggest that COVID-19 may be an important modifier of the onset, characteristics and outcome of acute ischaemic stroke.

25 May 2021 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
TATalal Al-Mayhani
Talal Al-Mayhani
SSSadia Saber
Sadia Saber
MSMatthew J Stubbs
Matthew J Stubbs
NLNicholas A Losseff
Nicholas A Losseff
RPRichard J Perry
Richard J Perry
DWDavid J Werring
David J Werring

9 June 2020 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
SLSoon Tjin Lim
Soon Tjin Lim
VTVincent Thijs
Vincent Thijs
SMStephen J. X. Murphy
Stephen J. X. Murphy
IFIsrael Fernandez
Israel Fernandez
JMJoan Montaner
Joan Montaner
DMDominick J. H. McCabe
Dominick J. H. McCabe
Background The prevalence of ex vivo ‘high on-treatment platelet reactivity (HTPR)’ and its relationship with recurrent vascular events/outcomes in patients with ischaemic cerebrovascular disease (CVD) is unclear. Methods A systematic review and meta-analysis was performed in accordance with the PRISMA statement. MEDLINE, EMBASE and Cochrane Library were searched for completed manuscripts until May 2019 on TIA/ischaemic stroke patients, ≥ 18 years, treated with commonly-prescribed antiplatelet therapy, who had platelet function/reactivity testing and prospective follow-up data on recurrent stroke/TIA, myocardial infarction, vascular death or other cerebrovascular outcomes. Data were pooled using random-effects meta-analysis. Primary outcome was the composite risk of recurrent stroke/TIA, myocardial infarction or vascular death. Secondary outcomes were recurrent stroke/TIA, severe stroke (NIHSS > 16) or disability/impairment (modified Rankin scale ≥ 3) during follow-up. Results Antiplatelet–HTPR prevalence was 3–65% with aspirin, 8–56% with clopidogrel and 1.8–35% with aspirin–clopidogrel therapy. Twenty studies (4989 patients) were included in our meta-analysis. There was a higher risk of the composite primary outcome (OR 2.93, 95% CI 1.90–4.51) and recurrent ischaemic stroke/TIA (OR 2.43, 95% CI 1.51–3.91) in patients with vs. those without ‘antiplatelet–HTPR’ on any antiplatelet regimen. These risks were also more than twofold higher in patients with vs. those without ‘aspirin–HTPR’ and ‘dual antiplatelet–HTPR’, respectively. Clopidogrel–HTPR status did not significantly predict outcomes, but the number of eligible studies was small. The risk of severe stroke was higher in those with vs. without antiplatelet–HTPR (OR 2.65, 95% CI 1.00–7.01). Discussion Antiplatelet–HTPR may predict risks of recurrent vascular events/outcomes in CVD patients. Given the heterogeneity between studies, further prospective, multi-centre studies are warranted.

29 June 2020 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
RPRichard Perry
Richard Perry
ABAzra Banaras
Azra Banaras
DWDavid J. Werring
David J. Werring
RSRobert Simister
Robert Simister

1 July 2015 in Survey of Ophthalmology
Verified
Journal Article
Closed access
MLMitchell Lawlor
Mitchell Lawlor
RPRichard Perry
Richard Perry
BHBeverley Jane Hunt
Beverley Jane Hunt
GPGordon Terence Plant
Gordon Terence Plant